Insight updating of the molecular hallmarks in ovarian carcinoma

Q3 Medicine Ejc Supplements Pub Date : 2020-08-01 DOI:10.1016/j.ejcsup.2019.11.001
Alba Mota PhD , Sara S Oltra PhD , Gema Moreno-Bueno PhD
{"title":"Insight updating of the molecular hallmarks in ovarian carcinoma","authors":"Alba Mota PhD ,&nbsp;Sara S Oltra PhD ,&nbsp;Gema Moreno-Bueno PhD","doi":"10.1016/j.ejcsup.2019.11.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and purpose</h3><p>Ovarian cancer (OC) is the deadliest gynaecologic cancer characterised by a high heterogeneity not only at the clinical point of view but also at the molecular level. This review focuses on the new insights about the OC molecular classification.</p></div><div><h3>Materials and methods</h3><p>We performed a bibliographic search for different indexed articles focused on the new molecular classification of OC. All of them have been published in PubMed and included information about the most frequent molecular alterations in OC confirmed by omics approaches. In addition, we have extracted information about the role of liquid biopsy in the OC diagnosis and prognosis.</p></div><div><h3>Results</h3><p>New molecular insights into OC have allowed novel clinical entities to be defined. Among OC, high-grade serous ovarian carcinoma (HGSOC) which is the most common OC is characterised by omics approaches, mutations in <em>TP53</em> and in other genes involved in the homologous recombination repair, especially <em>BRCA1/2</em>. Recent studies in HGSOC have allowed a new molecular classification in subgroups according to their mutational, transcriptional, methylation and copy number variation signatures with a real impact in the characterisation of new therapeutic targets for OC to be defined. Furthermore, despite the intrinsic intra-tumour heterogeneity, the advances in next generation sequencing (NGS) analyses of ascetic liquid from OC have opened new ways for its characterisation and treatment.</p></div><div><h3>Conclusions</h3><p>The advances in genomic approaches have been used for the identification of new molecular profiling techniques which define OC subgroups and has supposed advances in the diagnosis and in the personalised treatment of OC.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"15 ","pages":"Pages 16-26"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2019.11.001","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634919300011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 10

Abstract

Background and purpose

Ovarian cancer (OC) is the deadliest gynaecologic cancer characterised by a high heterogeneity not only at the clinical point of view but also at the molecular level. This review focuses on the new insights about the OC molecular classification.

Materials and methods

We performed a bibliographic search for different indexed articles focused on the new molecular classification of OC. All of them have been published in PubMed and included information about the most frequent molecular alterations in OC confirmed by omics approaches. In addition, we have extracted information about the role of liquid biopsy in the OC diagnosis and prognosis.

Results

New molecular insights into OC have allowed novel clinical entities to be defined. Among OC, high-grade serous ovarian carcinoma (HGSOC) which is the most common OC is characterised by omics approaches, mutations in TP53 and in other genes involved in the homologous recombination repair, especially BRCA1/2. Recent studies in HGSOC have allowed a new molecular classification in subgroups according to their mutational, transcriptional, methylation and copy number variation signatures with a real impact in the characterisation of new therapeutic targets for OC to be defined. Furthermore, despite the intrinsic intra-tumour heterogeneity, the advances in next generation sequencing (NGS) analyses of ascetic liquid from OC have opened new ways for its characterisation and treatment.

Conclusions

The advances in genomic approaches have been used for the identification of new molecular profiling techniques which define OC subgroups and has supposed advances in the diagnosis and in the personalised treatment of OC.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卵巢癌分子标记的新进展
背景和目的卵巢癌(OC)是最致命的妇科癌症,其特点是不仅在临床角度而且在分子水平上具有高度异质性。本文综述了近年来对OC分子分类的新认识。材料和方法我们对不同的索引文章进行了文献检索,重点研究了OC的新分子分类。所有这些研究都发表在PubMed上,其中包括通过组学方法证实的OC中最常见的分子改变的信息。此外,我们还提取了液体活检在OC诊断和预后中的作用。结果对OC的新分子认识使得新的临床实体得以定义。在卵巢癌中,最常见的高级别浆液性卵巢癌(high-grade serous ovarian carcinoma, HGSOC)以组学方法、TP53和其他参与同源重组修复的基因突变(尤其是BRCA1/2)为特征。最近对HGSOC的研究允许根据其突变、转录、甲基化和拷贝数变异特征对亚群进行新的分子分类,这对定义OC的新治疗靶点的特征具有真正的影响。此外,尽管存在固有的肿瘤内异质性,但卵巢癌禁欲液的下一代测序(NGS)分析的进展为其表征和治疗开辟了新的途径。基因组学方法的进步已被用于鉴定新的分子谱技术,这些技术可以定义OC亚群,并有望在OC的诊断和个性化治疗方面取得进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ejc Supplements
Ejc Supplements 医学-肿瘤学
自引率
0.00%
发文量
0
审稿时长
3.7 months
期刊介绍: EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites. EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention. Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief. EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).
期刊最新文献
99mTc/123I Dual-Radionuclide Correction for Self-Scatter, Down-Scatter, and Tailing Effect for a CZT SPECT with Varying Tracer Distributions. Pre-COVID-19 Disparities in Telemedicine Use Among Louisiana Medicaid Beneficiaries. The importance of basal-temporal white matter to pre- and post-surgical naming ability in temporal lobe epilepsy. Editorial board Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1